Compare ARDX & KOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | KOP |
|---|---|---|
| Founded | 2007 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Forest Products |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 797.8M | 784.7M |
| IPO Year | 2014 | 2005 |
| Metric | ARDX | KOP |
|---|---|---|
| Price | $3.02 | $41.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 2 |
| Target Price | $12.80 | ★ $57.00 |
| AVG Volume (30 Days) | ★ 4.3M | 131.9K |
| Earning Date | 11-03-2026 | 11-06-2026 |
| Dividend Yield | N/A | ★ 0.87% |
| EPS Growth | N/A | ★ 11.38 |
| EPS | ★ N/A | N/A |
| Revenue | $2,607,000.00 | ★ $1,879,300,000.00 |
| Revenue This Year | $19.21 | $3.14 |
| Revenue Next Year | $28.19 | $3.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.96 | $25.00 |
| 52 Week High | $8.40 | $53.00 |
| Indicator | ARDX | KOP |
|---|---|---|
| Relative Strength Index (RSI) | 37.18 | 43.62 |
| Support Level | N/A | $38.72 |
| Resistance Level | $3.35 | $42.17 |
| Average True Range (ATR) | 0.13 | 1.23 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 15.19 | 52.95 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Koppers Holdings Inc through its subsidiaries, manufactures and sells wood products, wood treatment chemicals, and carbon compounds used in markets such as railroad, aluminum and steel, agriculture, utilities, and residential lumber. The company is organized into three business segments: railroad and utility products and services, performance chemicals, and carbon materials and chemicals. Its product portfolio includes treated and untreated wood products like crossties used in railroads, wood preservation chemicals, and carbon compounds such as creosote used in the treatment of wood crossties, among others. The majority of its revenue comes from the company's railroad and utility products and services segment, and more than half of the company's revenue is earned in the United States.